CA1-18 Tumor Marker Assay for Early Detection and Diagnosis of Colorectal Cancer
Filed in archive Diagnostics, Methodologies and Instrumentation on October 16, 2006
EDP Biotech Corporation has developed an immunodiagnostic test for colorectal cancer called CA1-18 Enzyme Immunoassay (EIA).
The CA1-18 test is a monoclonal-polyclonal sandwich EIA for the quantitative measurement of CA1-18 (Tennessee Antigen) in human serum. Tennessee Antigen, a tumor-associated antigen, is present in elevated levels in the serum of patients with various carcinomas, particularly colorectal cancer.
The diagnostic test is now available to research customers, and DP plans to submit the CA1-18 EIA to the U.S. Food and Drug Administration (FDA) for marketing clearance in April 2007.
Source: MarketWire
[Image: See larger version from EDP Biotech]
Tags: diagnostics colon+cancer cancer colorectal+cancer immunoassay biotech early+detection marker+assay
Vote for CA1-18 Tumor Marker Assay for Early Detection and Diagnosis of Colorectal Cancer:
|
Rating: 5.17 out of 6 vote(s) cast.
|
Response from:
Trusted.MD Network
The American Cancer Society (ACS) has launched an online video community called SharingHope.tv.
A lot like YouTube, but the essence is that, it is a venue where cancer patients, survivors and their families can share their stories, triumphs, as well as
Response from:
Trusted.MD Network
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells